...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Friedreich’s Ataxia Therapy News - Very interesting

BDAZ, I believe that as long as the RVX-208 label does not claim an effect on patients suffering from FA, there are no problems with the Pfizer patent application (should it be granted). Any MD can prescribe RVX-208 off label to a patient with FA. However, if Resverlogix should claim that there is an effect of RVX-208 on FA, I guess that Resverlogix would have to come to some agreement with Pfizer. Anyway, I think this is very hypothetical.

Share
New Message
Please login to post a reply